Trial Outcomes & Findings for Pembrolizumab in Elderly Patients With Advanced Lung Cancer (NCT NCT03293680)

NCT ID: NCT03293680

Last Updated: 2024-10-23

Results Overview

Defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

83 participants

Primary outcome timeframe

From the date of inclusion of the first patient to until end of follow up, up to 36 months.

Results posted on

2024-10-23

Participant Flow

A total of 83 patients were recruited between January 2017 and November 2019 and 82 patients received treatment. Of these, 74 patients were finally analysed since eight were inclusion errors.

Participant milestones

Participant milestones
Measure
Pembrolizumab Arm
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Overall Study
STARTED
83
Overall Study
COMPLETED
74
Overall Study
NOT COMPLETED
9

Reasons for withdrawal

Reasons for withdrawal
Measure
Pembrolizumab Arm
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Overall Study
Death
1
Overall Study
Did not meet inclusion criteria
8

Baseline Characteristics

Pembrolizumab in Elderly Patients With Advanced Lung Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pembrolizumab Arm
n=74 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Age, Continuous
78.1 years
STANDARD_DEVIATION 5.50 • n=93 Participants
Sex: Female, Male
Female
10 Participants
n=93 Participants
Sex: Female, Male
Male
64 Participants
n=93 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=93 Participants
Race (NIH/OMB)
Asian
0 Participants
n=93 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=93 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=93 Participants
Race (NIH/OMB)
White
74 Participants
n=93 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=93 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=93 Participants
Region of Enrollment
Spain
74 participants
n=93 Participants
Histology
Adenocarcinoma
32 Participants
n=93 Participants
Histology
Squamous
33 Participants
n=93 Participants
Histology
Large cell carcinoma
2 Participants
n=93 Participants
Histology
Aden squamous
1 Participants
n=93 Participants
Histology
Not otherwise specified / Undifferentiated
6 Participants
n=93 Participants
Current cancer stage
IIIB
6 Participants
n=93 Participants
Current cancer stage
IV
68 Participants
n=93 Participants
Previous antineoplastic treatments
Radiotherapy
24 participants
n=93 Participants
Previous antineoplastic treatments
Surgery
9 participants
n=93 Participants
Previous antineoplastic treatments
Adjuvant chemotherapy
6 participants
n=93 Participants
Previous antineoplastic treatments
Concurrent chemoradiotherapy
5 participants
n=93 Participants
Previous antineoplastic treatments
Neo-adjuvant chemotherapy
2 participants
n=93 Participants
Previous antineoplastic treatments
No therapy
28 participants
n=93 Participants
PD-L1
1-19%
16 Participants
n=93 Participants
PD-L1
20-49%
23 Participants
n=93 Participants
PD-L1
≥50%
35 Participants
n=93 Participants
ECOG performance Status at diagnosis
ECOG 0
18 Participants
n=93 Participants
ECOG performance Status at diagnosis
ECOG 1
56 Participants
n=93 Participants
Smoking history
Never (≤100 cigarettes/lifetime)
11 Participants
n=93 Participants
Smoking history
Former smoker (≥1 year)
51 Participants
n=93 Participants
Smoking history
Current smoker
12 Participants
n=93 Participants

PRIMARY outcome

Timeframe: From the date of inclusion of the first patient to until end of follow up, up to 36 months.

Population: We performed the analyses on the intention-to-treat (ITT) population.

Defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=74 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Overall Survival
19.2 Months
Interval 11.3 to 25.5

SECONDARY outcome

Timeframe: Beginning of cycle 1 (week 1) and beginning of cycle 18 (week 54) (each cycle is 3 weeks)

Population: Intention to treat population

To evaluate changes in health-related quality of life in responder and non-responder patients older than 70 years with advanced non-small cell lung cancer. QLQ-C30 Quality of Life Questionnaire. The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of multi-item scales and single items. All EORTC QLQ-C30 scale scores range from 0 to 100. A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom- atology

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=74 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Changes in Health-related Quality of Life With Lung Cancer Symptom Scale
At the beginning of the first cycle
66.7 units on a scale
Interval 16.7 to 100.0
Changes in Health-related Quality of Life With Lung Cancer Symptom Scale
At the beginning of the eighteenth cycle
92.3 units on a scale
Interval 72.3 to 100.0

SECONDARY outcome

Timeframe: Beginning of cycle 1 (week 1), beginning of cycle 4 (week 12), beginning of cycle 7 (week 21), beginning of cycle 10 (week 30), beginning of cycle 13 (week 39), beginning of cycle 16 (week 48) and beginning of cycle 18 (week 54) (each cycle is 3 weeks)

Population: Intention to treat population

To evaluate the impact on functional geriatric assessments of patients older than 70 years with advanced non-small cell lung cancer. The Barthel Index assesses activities in two major categories: Personal care and mobility. The personal care items include tasks such as drinking from a cup, dressing, grooming, bathing, and bowel and bladder continence. The scoring is as follows: scores of 0-20 indicate "total" dependency. scores of 21-60 indicate "severe" dependency. scores of 61-90 indicate "moderate" dependency. scores of 91-99 indicate "slight" dependency, score of 100 indicate independent.

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=74 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 18
97 units on a scale
Interval 90.0 to 100.0
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 10
100 units on a scale
Interval 75.0 to 100.0
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 1
100 units on a scale
Interval 50.0 to 100.0
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 4
100 units on a scale
Interval 76.0 to 100.0
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 7
100 units on a scale
Interval 65.0 to 100.0
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 13
100 units on a scale
Interval 70.0 to 100.0
Impact on Functional Assessments Measured With Barthel Scale
At the beginning of Cycle 16
100 units on a scale
Interval 58.0 to 100.0

SECONDARY outcome

Timeframe: From the inclusion date in the study until first progression or end of follow up, up to 36 months

Population: It is performed the analyses on the intention-to-treat (ITT) population.

To describe Progression-free Survival (PFS), according to RECIST criteria v. 1.1 of the first-line treatment with pembrolizumab (MK-3475) in elderly patients with advanced NSCLC. PFS defined as the length of time from the date of randomization to the date of the first documented progression of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=74 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Progression-free Survival (PFS)
6.1 Months
Interval 4.6 to 8.6

SECONDARY outcome

Timeframe: From the date of inclusion of the first patient until two years follow up visit, up to 24 months

Population: Intention to treat population

To evaluate the overall survival percentage of the patients included at two years

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=74 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Overall Survival Rate at 2 Years.
40.2 percentage of participants
Interval 28.6 to 51.5

SECONDARY outcome

Timeframe: From the initiation of treatment until end of follow up, up to 36 months

Population: It is performed the analyses on the intention-to-treat (ITT) population.

Defined as the length of time from the date of the start of the treatment that patients diagnosed with the disease and PD¨-L1 under 50% are still alive.

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=39 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
OS for Patients With a PD-L1 Under 50%
16.5 Months
Interval 6.8 to 24.6

SECONDARY outcome

Timeframe: From the initiation of treatment until end of follow up, up to 36 months

Population: It is performed the analyses on the intention-to-treat (ITT) population.

Defined as the length of time from the start of the treatment that patients diagnosed with the disease and PD-L1 greater than or equal to 50% are still alive.

Outcome measures

Outcome measures
Measure
Pembrolizumab Arm
n=35 Participants
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
OS for Patients With a PD-L1 Greater Than or Equal to 50%
23.3 Months
Interval 14.8 to 36.0

Adverse Events

Pembrolizumab Arm

Serious events: 46 serious events
Other events: 59 other events
Deaths: 46 deaths

Serious adverse events

Serious adverse events
Measure
Pembrolizumab Arm
n=74 participants at risk
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Progression disease
48.6%
36/74 • Number of events 36 • 36 months
The severity of AE will be determined using CTCAE version 4.03
General disorders
Other causes of death
13.5%
10/74 • Number of events 10 • 36 months
The severity of AE will be determined using CTCAE version 4.03

Other adverse events

Other adverse events
Measure
Pembrolizumab Arm
n=74 participants at risk
1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks Pembrolizumab: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Investigations
Platelet count decreased
8.1%
6/74 • Number of events 6 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Investigations
Increased creatinine level
6.8%
5/74 • Number of events 5 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Blood and lymphatic system disorders
Anemia
5.4%
4/74 • Number of events 4 • 36 months
The severity of AE will be determined using CTCAE version 4.03
General disorders
Fatigue
31.1%
23/74 • Number of events 23 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Gastrointestinal disorders
Diarrhoea
18.9%
14/74 • Number of events 14 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Respiratory, thoracic and mediastinal disorders
Pneumonitis
8.1%
6/74 • Number of events 6 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Skin and subcutaneous tissue disorders
Dry skin
16.2%
12/74 • Number of events 12 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Skin and subcutaneous tissue disorders
Pruritus
25.7%
19/74 • Number of events 19 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Skin and subcutaneous tissue disorders
Rash
14.9%
11/74 • Number of events 11 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Endocrine disorders
Hyperthyroidism
12.2%
9/74 • Number of events 9 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Skin and subcutaneous tissue disorders
Hypothyroidism
9.5%
7/74 • Number of events 7 • 36 months
The severity of AE will be determined using CTCAE version 4.03
Metabolism and nutrition disorders
Anorexia
16.2%
12/74 • Number of events 12 • 36 months
The severity of AE will be determined using CTCAE version 4.03

Additional Information

Eva Pereira

Fundación GECP

Phone: +34934302006

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place